Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 491

1.

Chronic complications of venous thromboembolism.

Winter MP, Schernthaner GH, Lang IM.

J Thromb Haemost. 2017 Aug;15(8):1531-1540. doi: 10.1111/jth.13741.

PMID:
28762624
2.

Nilotinib-induced vasculopathy: Identification of vascular endothelial cells as a primary target site.

Hadzijusufovic E, Albrecht-Schgoer K, Huber K, Hoermann G, Grebien F, Eisenwort G, Schgoer W, Herndlhofer S, Kaun C, Theurl M, Sperr WR, Rix U, Sadovnik I, Jilma B, Schernthaner GH, Wojta J, Wolf D, Superti-Furga G, Kirchmair R, Valent P.

Leukemia. 2017 Jul 31. doi: 10.1038/leu.2017.245. [Epub ahead of print]

PMID:
28757617
3.

Peripheral arterial disease outcomes and association with suPAR: A bridge to myeloid precursors or mast cells or both?

Hoebaus C, Yussuf SM, Valent P, Schernthaner GH.

Atherosclerosis. 2017 Jul 8. pii: S0021-9150(17)31182-6. doi: 10.1016/j.atherosclerosis.2017.07.007. [Epub ahead of print] No abstract available.

PMID:
28724499
4.

Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized MARLINA-T2D trial.

Groop PH, Cooper ME, Perkovic V, Hocher B, Kanasaki K, Haneda M, Schernthaner G, Sharma K, Stanton RC, Toto R, Cescutti J, Gordat M, Meinicke T, Koitka-Weber A, Thiemann S, von Eynatten M.

Diabetes Obes Metab. 2017 Jun 21. doi: 10.1111/dom.13041. [Epub ahead of print]

PMID:
28636754
5.

Variability in and predictors of glycaemic responses after 24 weeks of treatment with exenatide twice daily and exenatide once weekly.

Shaw JE, Gallwitz B, Han J, Hardy E, Schernthaner G.

Diabetes Obes Metab. 2017 Jun 1. doi: 10.1111/dom.13022. [Epub ahead of print]

PMID:
28573708
6.

Risk factors and mechanisms contributing to TKI-induced vascular events in patients with CML.

Valent P, Hadzijusufovic E, Hoermann G, Füreder W, Schernthaner GH, Sperr WR, Kirchmair R, Wolf D.

Leuk Res. 2017 May 12;59:47-54. doi: 10.1016/j.leukres.2017.05.008. [Epub ahead of print] Review.

PMID:
28549238
7.

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.

Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR; FOURIER Steering Committee and Investigators.

N Engl J Med. 2017 May 4;376(18):1713-1722. doi: 10.1056/NEJMoa1615664. Epub 2017 Mar 17.

PMID:
28304224
8.

Prevalence, glucose control and relative survival of people with Type 2 diabetes in the UK from 1991 to 2013.

Holden SE, Jenkins-Jones S, Morgan CL, Peters JR, Schernthaner G, Currie CJ.

Diabet Med. 2017 Jun;34(6):770-780. doi: 10.1111/dme.13332. Epub 2017 Mar 9.

PMID:
28173634
9.

Advances in the management of cardiovascular risk for patients with type 2 diabetes: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes.

Schernthaner G, Jarvis S, Lotan C, Prázný M, Wanner C, Wascher TC.

Ther Clin Risk Manag. 2017 Jan 13;13:69-79. doi: 10.2147/TCRM.S121804. eCollection 2017.

10.

YKL-40 and its complex association with metabolic syndrome, obesity, and cardiovascular disease.

Schernthaner GH, Höbaus C, Brix J.

Anatol J Cardiol. 2016 Dec;16(12):959. doi: 10.14744/AnatolJCardiol.2016.22332. No abstract available.

11.

Moderate alcohol consumption shifts to an atheroprotective phenotype: A glass of wine keeps atherosclerosis in check?

Schernthaner GH, Herz C, Stangl H.

Atherosclerosis. 2016 Nov;254:305-306. doi: 10.1016/j.atherosclerosis.2016.09.065. Epub 2016 Sep 22. No abstract available.

PMID:
27745703
12.

Center-based patient care enhances survival of elderly patients suffering from peripheral arterial disease.

Höbaus C, Herz CT, Obendorf F, Howanietz MT, Wrba T, Koppensteiner R, Schernthaner GH.

Ann Med. 2017 Jun;49(4):291-298. doi: 10.1080/07853890.2016.1241428. Epub 2016 Nov 12.

PMID:
27665938
13.

Inverse Relationship Between Organ-Specific Autoantibodies and Systemic Immune Mediators in Type 1 Diabetes and Type 2 Diabetes: Action LADA 11.

Schloot NC, Pham MN, Hawa MI, Pozzilli P, Scherbaum WA, Schott M, Kolb H, Hunter S, Schernthaner G, Thivolet C, Seissler J, Leslie RD; Action LADA Group.

Diabetes Care. 2016 Nov;39(11):1932-1939. Epub 2016 Aug 29.

PMID:
27573939
14.

Is the Use of DPP-4 Inhibitors Associated With an Increased Risk for Heart Failure? Lessons From EXAMINE, SAVOR-TIMI 53, and TECOS.

Schernthaner G, Cahn A, Raz I.

Diabetes Care. 2016 Aug;39 Suppl 2:S210-8. doi: 10.2337/dcS15-3009. No abstract available.

PMID:
27440835
15.

Canagliflozin provides greater attainment of both HbA1c and body weight reduction versus sitagliptin in patients with type 2 diabetes.

Schernthaner G, Lavalle-González FJ, Davidson JA, Jodon H, Vijapurkar U, Qiu R, Canovatchel W.

Postgrad Med. 2016 Nov;128(8):725-730. Epub 2016 Jul 26.

PMID:
27391951
16.

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.

Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB; LEADER Steering Committee; LEADER Trial Investigators.

N Engl J Med. 2016 Jul 28;375(4):311-22. doi: 10.1056/NEJMoa1603827. Epub 2016 Jun 13.

17.

Do we need a new classification system for arteriosclerotic lesions in crural limb ischemia? Pros and Cons.

Höbaus C, Herz C, Schernthaner GH.

Atherosclerosis. 2016 Aug;251:493-494. doi: 10.1016/j.atherosclerosis.2016.05.026. Epub 2016 May 27. No abstract available.

PMID:
27264505
18.

EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.

Schernthaner G, Schernthaner-Reiter MH, Schernthaner GH.

Clin Ther. 2016 Jun;38(6):1288-98. doi: 10.1016/j.clinthera.2016.04.037. Epub 2016 May 19.

PMID:
27210264
19.

Glucose-lowering therapy in type 2 diabetes. New hope after the EMPA-REG outcome trial.

Schernthaner G, Schernthaner GH.

Herz. 2016 May;41(3):208-16. doi: 10.1007/s00059-016-4427-3. Review.

20.

[Antihyperglycemic treatment guidelines for diabetes mellitus type 2].

Clodi M, Abrahamian H, Drexel H, Fasching P, Föger B, Francesconi C, Hoppichler F, Kaser S, Kautzky-Willer A, Lechleitner M, Ludvik B, Prager R, Fröhlich-Reiterer E, Roden M, Säly C, Schernthaner G, Sourij H, Toplak H, Wascher TC, Weitgasser R.

Wien Klin Wochenschr. 2016 Apr;128 Suppl 2:S45-53. doi: 10.1007/s00508-016-0991-z. German.

PMID:
27052250

Supplemental Content

Loading ...
Support Center